Nasdaq · Healthcare
BIO-TECHNE Corp (TECH)
As-reported financials and recent SEC filings for BIO-TECHNE Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.22B
Net income
$73.4M
Net margin
6.0%
Diluted EPS
$0.46
ROE
3.8%
P/E (TTM)
101.4×
Market cap
$11.06B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.22B | $1.16B | $1.14B | $1.11B | $931.0M |
| Gross profit | $790.3M | $769.7M | $769.8M | $756.5M | $632.9M |
| Operating income | $102.3M | $206.7M | $298.9M | $296.6M | $237.3M |
| Net income | $73.4M | $168.1M | $285.3M | $272.1M | $140.4M |
| Diluted EPS | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-26
View on EDGAR →DEFA14A2026-06-25
View on EDGAR →8-K2026-06-25
View on EDGAR →42026-06-04
View on EDGAR →SD2026-06-01
View on EDGAR →42026-05-12
View on EDGAR →1442026-05-08
View on EDGAR →42026-05-07
View on EDGAR →Go deeper on TECH
Search BIO-TECHNE Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.